Entyvio: payments to doctors
Payments that named Entyvio as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $131.5M
- Providers
- 28,739
- Transactions
- 273,661
- Average per transaction
- $480
The per-transaction average — $480 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 28,739 providers the average total is $4,574, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | $131,369,417 | 99.9% |
| Takeda | $64,594 | 0.0% |
| Takeda Pharmaceutical Company, Limited | $27,642 | 0.0% |
| Shire North American Group Inc | $631 | 0.0% |